Viridian Therapeutics, Inc. announced that the FDA has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterized by… read more.
Using a massage gun on or around the eyes risks major tearing and bruising to the retina—the light sensitive tissue at the back of the eye—doctors warn in… read more.
Outlook Therapeutics announced the FDA has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA for the treatment of neovascular age-related macular degeneration (nAMD),… read more.
Low concentration atropine eye drops are a safe and effective treatment for short-sightedness (myopia) in UK children, although the effects are small, suggests a clinical trial published by The BMJ today…. read more.
An AI-assisted model based on 71 different blood proteins could help doctors better predict retinal degeneration in diabetic patients before symptoms occur, according to a study published June… read more.
Treatment with CGRP inhibitors, a class of drugs used to prevent migraine, appears to be associated with a reduced risk of glaucoma, researchers reported on May 6, 2026… read more.
Groundbreaking research from the University of Houston shows that a single low-dose atropine eye drop can produce daylong effects in managing myopia, or nearsightedness, which affects roughly one-third of U.S…. read more.
EAHP Congress Highlights The use of autologous serum eye drops (ASED) was associated with promising real-world outcomes in patients with severe ocular surface diseases refractory to conventional treatment,… read more.
LENZ Therapeutics announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval… read more.
Amgen announced positive topline results from a Phase III trial of Tepezza (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid… read more.
Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ‘eye stroke’ (ischaemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an… read more.
Tenpoint Therapeutics, Ltd., announced that the FDA approved Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, the first and only dual-agent eye drop… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
